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Abstract
Background: Cytokines play a key role in the immune response to developing tumors, and therefore modulating
their levels and actions provides innovative strategies for enhancing the activity of antigen presenting cells and
polarizing towards T helper 1 type response within tumor microenvironment. One of these approaches could be
the employment of plant extracts that have cytokine immunomodulation capabilities. Previously, we have shown
that the Eriobotrya japonica hydrophilic extract (EJHE) induces proinflammatory cytokines in vitro and in vivo.
Methods: The present study explored the in vivo immunomodulatory effect on interferon-gamma (IFN-g),
interleukin-17 (IL-17), and transforming growth factor-beta 1 (TGF-b1) evoked by two water-extracts prepared from
EJ leaves in the tissues of normal and Meth-A-fibrosarcoma bearing mice.
Results: Intraperitoneal (i.p.) administration of 10 μg of EJHE and EJHE-water residue (WR), prepared from butanol
extraction, increased significantly IFN-g production in the spleen (p < 0.01) and lung (p < 0.03) tissues at 6-48
hours and suppressed significantly TGF-b1 production levels (p < 0.001) in the spleen for as long as 48 hours. The
latter responses, however, were not seen in Meth-A fibrosarcoma-bearing mice. On the contrary, triple i.p.
injections, 24 hours apart; of 10 μg EJHE increased significantly IFN-g production in the spleen (p < 0.02) while only
EJHE-WR increased significantly IFN-g, TGF-b1 and IL-17 (p < 0.03 - 0.005) production within the tumor
microenvironment of Meth-A fibrosarcoma. In addition, the present work revealed a significant prolongation of
survival time (median survival time 72 days vs. 27 days of control, p < 0.007) of mice inoculated i.p. with Meth-A
cells followed by three times/week for eight weeks of i.p. administration of EJHE-WR. The latter prolonged survival
effect was not seen with EJHE.
Conclusions: The therapeutic value of EJHE-WR as an anticancer agent merits further investigation of
understanding the effect of immunomodulators’ constituents on the cellular components of the tissue
microenvironment. This can lead to the development of improved strategies for cancer treatment and thus
opening up a new frontier for future studies.
Background
Multiple innate and adaptive immune effector cells and
molecules partake in the recognition and destruction of
cancer cells to protect against growing tumors, a con-
cept that is known as cancer immune surveillance.
Unfortunately, cancer cells are capable of avoiding this
process by immunoselection of poorly immunogenic
tumor cells along with subversion of the immune system
and thus shaping both the tumor and its microenviron-
ment [1]. Cytokines represent part of the complex pat-
tern of the immune response which can assist the
development of cancer as well as to eliminate it. Simul-
taneously, a large number of cytokines may be involved
in the complex interactions between host and tumor
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the immune system, can regulate tumor growth and
metastasis [2].
T h ef a i l u r eo ft h ei m m u n es y s t e mt or e c o g n i z ea n d
eradicate cancer cells may partly be a result of insuffi-
cient immunological activation. It is now increasingly
recognized that the microenvironment plays a critical
role in the progression of tumors where immune-resis-
tant tumor variants are selected, thereby initiating the
process of cancer immunoediting. One variable that
might prove conclusive in modulating the host reaction
is the mixture of cytokines produced within tumor
microenvironment [2,3]. Meanwhile, local activation of
the immune system at the tumor microenvironment site
can be achieved by experimental transfer and expression
of cytokine genes in tumor cells [2,3]. Interestingly,
cytokines in cancer can function in bidirectional way as
both; causative agents and potential treatments thusly
necessitating in-depth knowledge of the role of all the
various cytokines which in turn provides new opportu-
nities for improving cancer immunotherapy.
Several medicinal plants are considered immunomo-
dulatory as they display cytokine modulation and have
antitumoral effects. Of these are the leaves of Eriobotrya
japonica EJ Lindl (Rosaceae). Traditionally, EJ has been
used for treating lung, stomach diseases and diabetes
and has been found to be effective in chronic bronchitis,
inflammatory diseases, and against certain tumors [4-8].
A number of biologically active compounds have been
reported in the leaves of this plant for instance, polyphe-
nols, tannins, flavonoids, triterpenes, megastigmane gly-
cosides, and sesquiterpenes [4-6,9]. Many of these
biologically active compounds were correlated to cyto-
toxic, antimutagenic and antitumor effects in mouse
tumor models and human oral tumor cell lines [4-6].
Previously, we have shown that the hydrophilic leaf
extract of EJ, EJHE, induces and modulates in vitro and
in vivo proinflammatory cytokines production, IL-12,
IFN-g and tumor necrosis factor-alpha (TNF-a)m o r e
than an anti-inflammatory cytokine, IL-10 [10]. The pre-
sent study extended the latter observation of EJHE mod-
ulatory effects on IFN-g,T G F - b1 as a representative of
T regulatory (Treg) cells, and IL-17 as an indicator of T
helper (Th) 17 cells in normal tissues as well as in
Meth-A-fibrosarcoma tumor-bearing mice [11]. It has
been shown that IFN-g,I L - 1 7a n dT G F - b1 are capable
of exerting multiple effects within the tumor microen-
vironment [12-14]. Controversially, many of the exerted
effects are contextual hence, compelling further investi-
gations in that regard along with any attempt of their
immunomodulation that should be approached with a
definite knowledge of the initial level of cytokines and
their complex interaction with particular type of tumors
and the immune cells.
Taken into account the extraction method which
provokes key role in natural products and ultimately
may or may not modulate the immune function EJHE
was further extracted with n-butanol. The non-
extracted material was referred to as water residue
(EJHE-WR). EJHE-WR has been shown to induce more
of IFN-g than EJHE [10]. EJHE or EJHE-WR provides
possible ways to reestablish antitumor immune
response which can be further exploited for cancer
therapy and thereby reducing the complications due to
toxicity associated with cytokines systemic administra-
tion [15]. Altogether, the main objective of this study
was to examine EJHE and EJHE-WR possible treat-
ment of Meth-A, 3-methylcholanthrene (MCA)-
induced fibrosarcoma, through the manipulation of the
cytokine triad mentioned previously along with deeper
exploration of this cytokine trilogy synergistic or
antagonistic interactions with respect to tumor immu-
nity at the tumor microenvironment.
Methods
Plant material
Fresh leaves of EJ LINDL (Rosaceae) were collected
from Jabal Al Hussein area in Amman-Jordan (06/2009),
washed extensively with tap water, dried for one week at
room temperature, and then grounded into powder. The
plant material was identified in comparison with authen-
tic EJ obtained from the Botanical Institute, University
of Cologne (Germany).
Plant material extraction
Five hundred grams of powdered leaves were thor-
oughly extracted with boiled water. In portions, boiled
water (300 ml) was added to 50 g powder for five min-
utes followed by filtration into a flask. This step was
repeated three times. The native liquid EJHE was com-
b i n e da tt h ee n do ft h i ss t e pg i v i n gat o t a lv o l u m eo f2
liters. A part of the combined native liquid EJHE (300
ml) was freeze dried to obtain 8.93 g of the EJHE. The
remaining (1700 ml) of the combined native liquid
EJHE was successively partitioned with n-butanol (1:1).
Each portion of the remaining native EJHE was repeat-
edly extracted (three times or until solution became
clear) with n-butanol. The water phase, non-extracted
material, was combined at the end of this step and
referred to as EJHE-WR. A part of the combined liquid
EJHE-WR (300 ml) was freeze dried to obtain 10.76 g
of the EJHE-WR.
Before utilization in animal testing, each of EJHE or
EJHE-WR was dissolved in endotoxin-free phosphate
buffered saline (PBS) and sterilized through filtration
with sterile filters (0.2 μm). Then, the required concen-
trations were subsequently prepared in endotoxin-free
PBS and used fresh for each experiment.
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establishment of tumor cell line
Endotoxin-free Dulbecco’s PBS without calcium and
magnesium, PRMI-1640, fetal bovine serum (FBS), and
penicillin-streptomycin were purchased from Euroclone
(Siziano, Italy). Trypsin was obtained from PAA Labora-
tories Gmbh (Linz, Austria). Igepal CA-630, MCA 98%,
and lipopolycaccharide (LPS, L-6143) were obtained
from Sigma (St. Louis, MO, USA). T75 flasks were pur-
chased from Costar (Cambridge, MA, USA). Maxisorb
96-well flat bottom plates were purchased from Nunc
International (Roskilde, Denmark).
Mice
BALB/c males and females mice were utilized through-
out the experiments as indicated. BALB/c mice were
purchased from Yarmouk University (Irbid, Jordan).
Animals were housed on a 12:12 hr light cycle at 22 ±
2°C with food and water available ad libitum. All animal
experiments were performed in compliance with rele-
vant laws and institutional guidelines following the
approval of the Ethics Committee of Petra University
(Amman, Jordan).
Cytokine extraction following administration of extracts
To choose the best possible dose for the cytokine-
induced modulation over time by the two extracts, four
different doses/5 mice/group prepared in 1 ml of sterile
P B Sw e r ec h o s e n0 ,1 ,1 0a n d1 0 0μgo fE J H Ea n d
EJHE-WR and were administered i.p. into 8-10 weeks
old mice. After 2 hours, mice were sacrificed by cervical
dislocation and tissues/organs were collected within 5-
10 minutes. The collected tissues/organs were blood,
lungs, and spleen. Post sacrificing each mouse blood
was directly collected from the cardiac chamber, placed
into pre-chilled tube, weighed and incubated with 2 ml
of ice-cold endotoxin-free PBS containing 0.1% Igepal
CA-630 under ice [11]. After blood collection, the lungs,
spleen, and tumor were removed from mice, weighed,
placed in pre-chilled tube containing 2 ml of ice-cold
endotoxin-free PBS with 0.1% Igepal CA-630, and incu-
bated for 10 minutes on ice. The tissues were then
homogenized with a tissue disrupter (Janke and Kundle),
centrifuged (6000 rpm for 6 minutes), and the superna-
tant was transferred to labeled microcentrifuge tubes
and stored -30°C till cytokine assays [11].
The modulatory effect of 10 μg EJHE or EJHE-WR on
IFN-g,I L - 1 7a n dT G F - b1 tissue levels and in compari-
son to 2 μg of LPS were performed using fifty-two male
mice of 8-10 weeks old. Following a single i.p. injection,
mice were sacrificed from each group by cervical dislo-
cation at specific time points (0, 2, 6, 24 and 48 hours)
and blood, lungs, and spleen were collected as described
above.
MCA-induced tumors, cell lines preparation and
inoculation
Mice (2-4 weeks old) were inoculated subcutaneously (s.c.)
into the right hind flank with 1 mg/mouse of MCA dis-
solved in olive oil. Mice were inspected weekly for tumor
development. When tumors reached a 1-2 cm in diameter,
mice were sacrificed and the primary MCA-induced
tumors were aseptically excised, cut into small pieces,
minced, treated with trypsin, and cultured in T75 flasks
containing PRMI-1640 medium supplemented with 10%
FBS, and antibiotics (100 U/ml penicillin and 100 μg/ml
streptomycin), at 37°C in a humidified atmosphere of 5%
CO2. The medium was changed every 2-3 days. Cells were
split by trypsinization to maintain logarithmic growth.
For inoculation, the harvested Meth-A cells were
counted and resuspended in endotoxin-free PBS to the
desired concentrations. A suspension of Meth-A cells
was inoculated s.c. in the right flank of the mouse to
establish a tumor model of Meth-A fibrosarcoma. In
this experimental system, twenty-one male mice and
thirty female mice were inoculated with 2 × 10
6 tumor
cells in 200 μl endotoxin-free PBS. Recipient mice were
inspected twice weekly. Tumor-bearing mice were
defined by the presence of a progressively growing
tumor with a diameter of ≥7 mm measured using a digi-
tal caliper. Noteworthy, following tumor inoculation the
mice behaved normally, no apparent suffering, and no
signs of pain or other disorders were noticed.
Cytokine modulation in Meth-A-tumor-bearing mice after
administration of EJHE and EJHE-WR
Tumor-bearing mice with progressively growing trans-
planted-tumors were divided into five groups each con-
s i s t i n go ft h r e et of i v em i c e .G r o u p s1a n d2w e r e
administered i.p. with 1 ml of 10 μg EJHE and EJHE-WR,
respectively. Group 3 was administered i.p. with 1 ml of
endotoxin-free PBS and considered as the control group.
Following 24 hours, mice from groups 1, 2, and 3 were
sacrificed. Groups 4 and 5 were administered i.p. with 1
ml of 10 μg EJHE and EJHE-WR, respectively, once every
24 hours for three consecutive days and then sacrificed
on the fourth day. Mice were sacrificed by cervical dislo-
cation then spleen and tumor were collected for cyto-
kines extraction as described above. This experiment was
performed twice and the pattern of cytokine change was
the same in the two experiments. Therefore, the data pre-
sented here were derived from a single experiment
Survival of Meth-A tumor-bearing mice after
administration of EJHE and EJHE-WR
Thirty female mice were divided into three groups each
consisting of ten mice. Mice were inoculated i.p. with 2
×1 0
6 Meth-A cells in 0.5 ml endotoxin-free PBS. Three
days after tumor inoculation, group 1 and 2 were
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WR, respectively. Group 3 was administered i.p. with
0.5 ml of endotoxin-free PBS and considered as the
control group. The mice in the three groups were
repeatedly administered for eight weeks with the corre-
sponding doses every 48 hours with one day off follow-
ing each three consecutive administrations. The weights
of the mice were documented before each administra-
tion. The mice in each group were observed daily to
monitor their survival. The survival time of the mice
was also recorded.
Cytokine assays
Measurements of mouse tissue-extracted cytokines
(IFN-g, IL-17, and TGF-b1) were accomplished by sand-
wich ELISAs developed in accordance with the manu-
facturer’s recommendations (Duoset R & D Systems,
UK. Plates were read at 450 nm by SCO GmbH (Dingel-
sadt, Germany) ELISA plate reader and absorbance was
transformed to cytokines concentrations (pg/ml) and
then to (pg/g) of tissues using a standard curve com-
puted on Excel sheet after transforming values to log to
construct a straight line on a log-log graph.
Statistical analysis
All data in the figures are presented as the mean ± stan-
dard error and assessed by using one way ANOVA ana-
lysis followed by a Tukey’s test (95% confidence) for
multiple comparisons (SPSS version 17). The survival
analysis was analyzed with Breslow test. P value of <
0.05 is considered statistically significant.
Results
Modulation of tissue IFN-g, IL-17 and TGF-b by EJHE and
EJHE-WR
To choose the best possible dose for the tissue cytokine-
induced modulation over time by the extracts and other
experiments, three different concentrations of EJHE and
EJHE-WR and two-hour time point following adminis-
tration were chosen [10]. Administration of EJHE (1-100
μg) significantly modulated and increased IFN-g and IL-
17 production in the spleen at 1 and 10 μg of EJHE (p <
0.0001 and p < 0.001 for IFN-g and IL-17, respectively)
(Figure 1A). At higher doses of EJHE (100 μg), however,
IFN-g and IL-17 levels were significantly less than the
control values (p < 0.001). As for EJHE-WR, 1 μg/ml
increased significantly IFN-g and IL-17 production in
the spleen (p < 0.05 and <0.001, respectively). This
increase was not observed at higher doses. In addition,
EJHE-WR at 1 and 10 μg, but not EJHE, suppressed sig-
nificantly TGF-b level in the spleen (p < 0.005 and
<0.001, respectively) (Figure 1A).
In blood, TGF-b levels were reduced after (1-100 μg)
of EJHE and 1 and 10 μg of EJHE-WR administrations
(p < 0.001 and <0.05, respectively), whereas blood IL-17
levels were not significantly modulated following either
dose of EJHE or EJHE-WR (p > 0.05) (Figure 1B). In the
lungs, 10 μg of EJHE-WR increased significantly IFN-g
level (p < 0.001) (Figure 1C).
Modulation of tissue IFN-g, IL-17 and TGF-b over 48 hours
by EJHE and EJHE-WR
The tissue cytokines study indicated that 10 μgo fe i t h e r
extract will be suitable dose for the kinetic study. A single
i.p. injection of 10 μg EJHE or EJHE-WR into mice
modulated significantly spleen cytokines level. EJHE or
EJHE-WR at 10 μg increased significantly IFN-g produc-
tion in the spleen at 6-48 hours post i.p. administration
(p < 0.01). The increase was highest 24 hours post
administration of EJHE-WR and EHJE (Figure 2A). On
the other hand, EJHE and EJHE-WR suppressed signifi-
cantly spleen TGF-b1p r o d u c t i o nl a s t i n g4 8h o u r sp o s t
administration (p < 0.001). The latter suppression was
highest 24 hours post administration and stayed till 48
hours (Figure 2A). As for Il-17, EJHE (10 μg) exhibited a
trend toward suppression of IL-17 level at 24 hours post
administration (p > 0.05). This EJHE-induced suppres-
sion was not observed at 48 hours post administration.
However, IL-17 levels did not change after i.p. adminis-
tration of EJHE-WR (p > 0.05) (Figure 2A). Furthermore,
i.p. administration of LPS increased significantly IFN-g
production over the first 6 hours of administration (p <
0.0001). This increase was accompanied with a significant
r e d u c t i o ni nT G F - b levels between 6-48 hours and with
no change in IL-17 levels (Figure 2A).
EJHE at 10 μg did not induce any significant change in
blood IFN-g or TGF-b levels for 48 hours following i.p.
administration (p > 0.05) but displayed a trend towards a
decrease by 25-52% in blood IL-17 production 24-48
hours post i.p. administration (p > 0.05). Contrariwise,
EJHE-WR displayed a trend towards an increase by 41-
98% in blood IFN-g levels between 6 to 48 hours post i.p.
administration (p > 0.05) with a trend towards a decrease
in TGF-b1 production 2 hours post administration (p >
0.05) and a trend towards an increase by 39% in blood
IL-17 production 6 hours following i.p. administration
(p > 0.05). LPS on the other hand, increased significantly
IFN-g production (311%) in blood 6 hours following i.p.
injection. This maximum increase subsided below basal
levels at 24 and 48 hours post administration (p <
0.0001) (Figure 2B). The latter modulation was accompa-
nied with a significant suppression in blood TGF-b1 pro-
duction over the first 6 hours post LPS administration
(p < 0.001) and a significant reduction of blood IL-17
production at 24 h (p < 0.05) (Figure 2B).
A single i.p. injection of EJHE or EJHE-WR modulated
the production of IFN-g levels in mice lung tissues.
EJHE-WR increased significantly IFN-g production in
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0.03). This increase was highest 6 hours post adminis-
tration by 87% followed by a decline at 48 hours. Simi-
larly, EJHE demonstrated a trend towards an increase in
IFN-g production for as long as 48 hours after adminis-
tration with a maximum increase (101%) noticed 24
hours post i.p. injection (p > 0.05). On the other hand,
neither EJHE nor EJHE-WR modulated IL-17 or TGF-b
levels in the lungs. Furthermore, a single i.p. administra-
tion of LPS increased significantly (101%) IFN-g produc-
tion in the lungs 2 hours after administration followed
by a decline over the next 6-48 hours after administra-
tion to lower levels than the basal IFN-g levels (p <
0.002) (Figure 2C). Similarly, LPS did not induce any
significant change in IL-17 levels in the lungs but
demonstrated a trend towards a decrease of TGF-b
levels over 2 to 24 hours post i.p. injection (Figure 2C).
Modulation of IFN-g, IL-17 and TGF-b1 in tumor-bearing
mice
Twenty four hours post a single administration of EJHE
or EJHE-WR (10 μg) did not modulate spleen or tumor
IFN-g,T G F - b and IL-17 production levels in tumor-
bearing mice (Figure 3A &3B). However, when either
extract was administered once daily for three consecu-
tive days, spleen IFN-g levels increased significantly by
E J H E( p<0 . 0 2 )a n ds h o w e dat r e n dt o w a r da ni n c r e a s e
by EJHE-WR (p >0.05) (Figure 3A). However, no
changes in IL-17 or TGF-b1 levels were observed (p >
0.05) (Figure 3A). In addition, such administration mod-
ality increased significantly IFN-g and IL-17 (p < 0.03)
as well as TGF-b1 (p < 0.005) production by EJHE-WR
within the tumor microenvironment of Meth-A-bearing
mice (Figure 3B). Although a triple consecutive i.p.
injections of EJHE showed trend toward increase in the
production of the three cytokines within tumor micro-
environment but without reaching statistical significance
(Figure 3B).
Survival of Meth-A tumor-bearing mice after treatment
with EJHE and EJHE-WR
Kaplan-Meier plots of mice inoculated i.p. with 2 × 10
6
Meth-A cells followed by injections of sterile PBS,
EJHE (10 μg), or EJHE-WR (10 μg) for eight weeks
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Figure 1 IFN-g,T G F - b and IL-17 production levels in the spleen (A), blood (B) and lungs (C) of mice at 2 hours following
administration of 0, 1, 10, and 100 μg EJHE or EJHE-WR (* indicates a significant increase or † indicates a significant decrease in
comparison to 0 μg, see text for details).
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The overall mortality patterns of the Meth-A-bearing
mice shows that i.p. administration of EJHE-WR pro-
longed significantly (p < 0.007) the life-span of Meth-A-
bearing mice with a median survival time of 78 days in
comparison to 27 days for the control group. On the
other hand, the mortality pattern of the EJHE treated
group was found to overlap with the control group indi-
cating that EJHE did not affect the survival of Meth-A-
bearing mice (Figure 4).
Discussion
Recently, it has been shown that water-extract of EJ,
termed EJHE, provides an affluent source of polysac-
charides and polar phenolic compounds such as pro-
cyanidins, flavonoid glycosides, and other molecules
that may induce or modulate cytokines production
providing distinguishable immunomodulatory and
putative anticancer activity [4,10]. Thus, the fractiona-
tion of EJHE with n-butanol (EJHE-WR) was per-
formed to concentrate polysaccharides, high molecular
weight oligomeric procyanidins and related polyphe-
nols and to exclude low molecular weight compounds
recovered by n-butanol, in order to enhance cytokine
modulatory activity [4].
Initially, three different concentrations of EJHE and
EJHE-WR were chosen (1, 10, and 100 μg/ml) and
their cytokine modulatory activities were sought in
mice organs, including spleen and lungs following two
hours of administration [10]. Collectively, this experi-
ment demonstrated that the in vivo favorable cytokines
modulatory effect in mice tissues as induction of IFN-g
and inhibition of TGF-b1 levels were best achieved by
10 μg of EJHE and EJHE-WR. Subsequently, the
selected concentration was further utilized to investi-
gate the tissue-specific effects of EJHE, EJHE-WR, in
comparison with LPS on IFN-g,I L - 1 7 ,a n dT G F - b1
production levels over 48 hours and demonstrated that
EJHE and EJHE-WR at 10 μg modulated and induced
in vivo cytokines production in tissue- and time-speci-
fic manner. Administration of EJHE and EJHE-WR (10
μg) induced IFN-g production in the spleen and lung
tissues at 2-48 hours, and in blood at 6-48 hours after
EJHE-WR administration only, whereas LPS induced
maximum IFN-g production in the spleen and blood at
6 hours, and at 2 hours in the lungs. Furthermore, the
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induction of IFN-g in the spleen, TGF-b1w a sd o w n -
regulated in response to EJHE and EJHE-WR adminis-
tration for as long as 48 hours. Likewise, blood, spleen,
and lungs TGF-b1 levels were down-regulated upon
LPS administration at 2-24, 2-48, and 2-24 hours,
respectively.
Earlier studies in vitro showed that low concentrations
of EJHE induced the production of proinflammatory
cytokines (IL-12, IFN-g,a n dT N F - a)w h i l s th i g h e rc o n -
centrations reduced the latter induction along with an
increase in anti-inflammatory cytokine; IL-10 [10]. Simi-
larly, water-extract of EJ leaves utilized at high concen-
trations inhibited LPS-induced proinflammatory
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from human mast cells and human lung epithelial cells,
respectively, likely by inhibiting Nuclear factor kappa B
(NF-B) activation [16,17]. The latter coincides with the
inhibition of proinflammatory cytokines and the increase
in anti-inflammatory cytokine; IL-10, at higher EJHE
concentrations [10]. Correspondingly, the data in the
present study demonstrated a similar action in vivo as
higher concentration (100 μg/ml) inhibited IFN-g pro-
duction in the spleen and lung tissues probably in a
likewise manner, i.e. inhibition to NFB, while on the
contrary lower concentration (1-10 μg/ml) induced IFN-
g production and could be through increasing NF-B
activity [18].
Since EJHE and EJHE-WR induced and modulated
cytokines in several organs, their cytokine modulatory
mechanism might be postulated by the compounds they
contain. These extracts contain mainly polysaccharides
and polar phenolic compounds like procyanidins and
flavonoid glycosides. Such compounds stimulate anti-
gen-presenting cells (APCs); dendritic ells (DCs) and
macrophages, via the expressed Toll-like Receptors
(TLRs) [19]. The latter cells induce IL-12 levels through
the activation of NF-B [10], and APCs-derived IL-12
may preferentially stimulate T and B cells in vivo
[20-23] (besides its action on NK cells) that in turn can
influence the development of Th1 response and thus
supports IFN-g production [24,25]. The recognition of
the polysaccharides with procyanidins and flavonoid gly-
cosides by TLRs-expressed on DCs, macrophages, as
well as B and T cell subtypes [22,26] induces subsequent
engagement of signaling pathways that explain the
timing of cytokine secretion pattern as apparent in IFN-
g highest induction at 2 or 6 hours upon LPS adminis-
tration versus 24-48 hours after EJHE and EJHE-WR
administration. Ostensibly, this differential induction
time proposes that molecules within EJHE and EJHE-
WR induce cytokine release in more complex pathways
involving several intracellular signaling in comparison
with LPS. Still, other non-immune cellular sources
could be implicated in the cytokines responses depicted
herein. Apart from immune cells, TLRs are expressed
on tissues such as the lung epithelial cells [27,28]. Type
2 alveolar epithelial cells, for instance, have been shown
to express mRNA for TLR2 and TLR4 and to have func-
tional response with the release of cytokines in response
to LPS [29].
M o r e o v e r ,i tc a n n o tb er u l e do u tt h a tt h ec h a n g e s
observed in the present study may occur when EJHE-,
EJHE-WR-, and LPS-induced IFN-g bind to T cell popu-
lations in a paracrine fashion probably via employment
of the JAK-STAT signaling pathway [30,31]. Generally,
within a period of hours, upon the accumulation of acti-
vated STATs in the nucleus the signal decays and the
STATs are re-exported back to the cytoplasm for a new
cycle of signaling [32]. IFN-g inhibits the TGF-b-
induced phosphorylation of Smad3, the subsequent
binding of Smad3 with Smad4, and the accumulation of
Smad3 in the nucleus. Furthermore, upon IFN-g signal-
ing through Jak1 and STAT1 proteins and activation of
NFB, IFN-g induces Smad7 expression which prevents
the interaction of Smad3 with the TGF-b receptor lead-
ing to inhibition of TGF-b signaling and so reduction in
its levels [33,34]. Probably, in this way, the crosstalk
between the IFN-g and TGF-b signals lead to the
changes depicted herein.
Furthermore, Treg cells expressing Foxp3 are major
source of TGF-b1 which regulates their generation as
well [35,36]. Mice with a T cell-specific deletion of the
Tgfb1 gene have enhanced Th1 cells proliferation, acti-
vation, and differentiation and TGF-b1, produced by
Foxp3
+ Treg cells, was required to inhibit Th1 cells dif-
ferentiation [36]. Therefore, TGF-b1 suppression upon
EJHE, EJHE-WR, and LPS administration supported
Th1 development and thus the enhanced IFN-g produc-
tion. Additionally, taking into account the delicate bal-
ance in the cytokines’ network, the information
conveyed by an individual cytokine depends on the pat-
tern of regulators to which a cell is exposed, and not on
one single cytokine [37]. Recent studies have established
that TGF-b1 not only regulates the generation of Foxp3
+
Treg cells but also acts as an essential regulator of
Th17 cell differentiation from naïve CD4
+ T cells
together with IL-6 [35,38,39]. In the current study, the
disappearance of a crucial cytokine for Th17 differentia-
tion as TGF-b1 in the spleen upon EJHE, EJHE-WR, and
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Figure 4 Kaplan-Meier plot of mice inoculated i.p. with 2 × 10
6
Meth-A cells followed by a three times a week injection of
sterile PBS, EJHE (10 μg), or EJHE-WR (10 μg) for eight weeks.
Significant prolongation (*p < 0.007) of survival following
administration of EJHE-WR-treated Meth-A-bearing mice was
observed.
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Th17 cells and thus predict no change in IL-17 levels
noticed herein.
Commonly, the immune system may be either com-
promised or suppressed in cancer patients. In view of
the cytokine modulatory effects of EJHE and EJHE-WR,
it was of considerable interest to investigate if adminis-
tration of EJHE and/or EJHE-WR can restore the bal-
ance of proinflammatory/anti-inflammatory cytokines in
the tumor microenvironment of Meth-A tumor-bearing
mice. In the present study, Meth-A cells were injected
into the s.c. layer which consists of loose connective tis-
sue permitting the injected cells to diffuse easily [40].
The local microenvironment of Meth-A cells adminis-
tered s.c. is complex since, besides fibroblasts, the
microenvironment can also comprise numerous types of
resident or infiltrating cells, like endothelial cells, mus-
cular cells as well as granulocytes, macrophages, and
lymphocytes [40,41]. The results from the present study
demonstrated that a single i.p. administration of 10 μg
EJHE and EJHE-WR did not modulate cytokines in the
spleen of tumor-bearing mice as seen in healthy mice as
well as in the tumor microenvironment. For instance, 24
hours post administration of EHJE or EJHE-WR, the
TGF-b to IFN-g ratio in the spleen of healthy mice
became ~30 in comparison to 300 in PBS-injected
mice whereas this ratio either did not change or
increased upon administration of EHJE and EHJE-WR
in tumor-bearing mice. This is due to the systemic
immunosuppressive behavior of the tumor and within
its environment which enhances the depolarization of
macrophages, DC and neutrophils, recruitment of Treg
cells within tumor microenvironment, and lodging of
the latter cells in lymphoid organs resulting in produ-
cing suppressive cytokine such as TGF-b [42]. Because
a single injection did not cause substantial change in
cytokine modulation in tumor-bearing mice, triple
injections once every 24 hours for three consecutive
days were thought to induce a significant cytokine
modulation. The latter regimen by EJHE increased
spleen IFN-g production whereas EJHE-WR increased
significantly IFN-g, and unexpectedly TGF-b1a n d
IL-17 production levels within the tumor microenvir-
onment of Meth-A-bearing mice.
The induction of IFN-g in the tumor microenviron-
ment and spleen of Meth-A-bearing mice by triple i.p.
injection of EJHE-WR and EJHE, respectively, is prob-
ably connected with their constituents enhancing effect
allowing the intratumoral penetration of antitumor
effectors and polarizing towards Th1 response from
macrophages and DCs produced IL-12 which in turn
can support IFN-g production noticed within the micro-
environment [43]. However, this favorable induction of
IFN-g by EJHE-WR within the tumor microenvironment
was accompanied by TGF-b1 induction, probably along
with an inflammatory cytokine e.g. TNF-a [10,42] that
is common in such microenvironment, may further sup-
ports Th17 differentiation and thus induce IL-17 pro-
duction as well [44]. This could be explained by the fact
that tumor-bearing mice have a systemic increase in
their depolarized immune cells (DC, macrophages, neu-
trophils) and Treg that would secrete more TGF-b upon
stimulation and have less polarized cells that enhance
DC-Th1 pathway to produce IFN-g [42,45]. Further-
more, repeated administration of EJHE or EJHE-WR
may resulted in an increase in tumor-infiltrating CD4
+CD25+Foxp3+ Treg cells that led to increase in TGF-b
in tumor microenvironment [42]. The latter note can
also explain the observed results in the spleen of tumor-
bearing mice. It is worth to investigate the various cellu-
lar populations that were recruited to or modulated in
the tumor microenvironment and spleen of Meth-A-
bearing mice upon repeated i.p. administration of EJHE
and EJHE-WR.
The present results also demonstrated a prolonged
survival of mice inoculated i.p. with Meth-A cells
throughout long period i.p. administration of EJHE-WR
in comparison with Meth-A-bearing mice treated with
EJHE (10 μg) and PBS. Previous work showed that a
fractionated water-extract of EJ leaves with butanol
recovered high molecular weight procyanidin oligomer
which displayed the highest cytotoxic activity in vitro
against two human oral tumor cell lines [4]. Particularly,
fractionation of EJHE with n-butanol to obtain EJHE-
WR provided an abundant source of high molecular
weight procyanidin oligomer together with polysacchar-
ides and polar phenolics compounds possessing low
anti-inflammatory activity, meanwhile, exerting immu-
nostimulating potentials [10] and can also be involved
in antitumor and cytotoxic activities [4]. In addition,
repeated EJHE-WR administration produced higher
IFN-g in the tumor microenvironment which should
enhance T cytotoxic and NK cell activities, as well as
increased endogenous IL-17 which was found to reduce
tumor growth [46]. Previous studies displayed critical
functions for IFN-g dependent tumor rejection of trans-
planted tumors and MCA-mediated tumorigenesis in
mice [47,48]. The immune response against Meth-A
tumor cells appeared to be closely associated with aug-
mented IFN-g production and CTL activity against
tumor which can injure tumor-feeding vessels in tumor
tissue [3,41]. However, further studies are needed to
clarify the antitumor activities of EJHE-WR constituents
involved in Meth-A bearing mice.
Conclusions
EJHE and EJHE-WR cytokine modulatory potentials
have been characterized in tissues from normal and
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factors partake in depicting the responses noticed
herein. In that respect, (i) the nature of the immunomo-
dulating agent that elicits the immune response in each
occasion, (ii) the type and timing of cytokine secretion
either by the stimulating APCs, T and B lymphocytes
through TLRs mediated pathways, or other onlooker
cell populations, and (iii) the impact of tissue/organ/
tumor being studied with its burden and phenotype of
residing cell populations th a ta l s oc a n n o tb ee x c l u d e d .
Furthermore, immunomodulators which can be used for
long period with minimum side effects are substantial in
the cancer therapy. Ordinarily, targeted cancer mono-
therapy can end up with bypass mechanisms which in
turn forced the employment of either combination ther-
apy or agents that interfere with multiple cell-signaling
pathways as a current paradigm for most treatments.
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